Skip to main content
    T

    Taysha Gene Therapies Inc (TSHA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.73
    +0.22 (+6.27%)

    Market Cap: $1.14B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    44%(11/25)
    Avg Surprise
    -74.74%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.14 - $-0.10
    4 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.12-2.5%
    60d ago$-0.12-4.2%
    30d ago$-0.12-4.2%
    7d ago$-0.130.0%
    Current$-0.13
    Revenue Consensus
    $618180
    Range$0 - $4M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.14
    Range$-0.25 - $-0.05
    5 analysts
    Revenue Consensus
    $-244690
    Range$-1994690 - $13M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.14---
    Sep 26EST
    		-$-0.13---
    Jun 26
    Reported Aug 11
    		$-0.13$-0.11-18.18%Miss-62.5%
    Mar 26
    Reported May 6
    		$-0.11$-0.10-10.00%Miss-37.5%
    Dec 25
    Reported Mar 19
    		$-0.07$-0.10+23.43%Beat-4.6%
    Sep 25
    Reported Nov 4
    		$-0.09$-0.09+0.00%Beat-28.6%
    Jun 25
    Reported Aug 12
    		$-0.08$-0.07-14.29%Miss+11.1%
    Mar 25
    Reported May 15
    		$-0.08$-0.08+0.00%Beat+20.0%
    Dec 24
    Reported Feb 26
    		$-0.07$-0.08+12.50%Beat-107.6%
    Sep 24
    Reported Nov 13
    		$-0.07$-0.09+22.22%Beat+92.5%
    Jun 24
    Reported Aug 12
    		$-0.09$-0.10+10.00%Beat+76.3%
    Mar 24
    Reported May 14
    		$-0.10$-0.09-11.11%Miss+64.3%
    Dec 23
    Reported Mar 19
    		$0.92$-0.11+936.36%Beat+192.9%
    Sep 23
    Reported Nov 14
    		$-0.93$-0.17-447.06%Miss-45.3%
    Jun 23
    Reported Aug 14
    		$-0.38$-0.31-22.58%Miss+54.8%
    Mar 23
    Reported May 11
    		$-0.28$-0.38+26.32%Beat+78.6%
    Dec 22
    Reported Mar 28
    		$-0.99$-0.33-200.00%Miss+25.0%
    Sep 22
    Reported Nov 8
    		$-0.64$-0.82+21.95%Beat+52.6%
    Jun 22
    Reported Aug 11
    		$-0.84$-1.06+20.75%Beat+22.9%
    Mar 22
    Reported May 16
    		$-1.31$-1.10-19.09%Miss-50.6%
    Dec 21
    Reported Mar 31
    		$-1.32$-1.25-5.60%Miss-26.9%
    Sep 21
    Reported Nov 10
    		$-1.35$-1.09-23.85%Miss-5.5%
    Jun 21
    Reported Aug 16
    		$-1.09$-0.86-26.74%Miss+14.8%
    Mar 21
    Reported May 11
    		$-0.87$-0.65-33.85%Miss-
    Dec 20
    Reported Mar 3
    		$-1.04$-0.37-181.08%Miss-
    Sep 20
    Reported Nov 12
    		$-1.28$0.07-1928.57%Miss-
    Jun 20
    Reported Sep 25
    		$-1.28$-1.28+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-9.25EV/EBITDAN/A
    Price/FCF-10.38xFCF Yield-9.63%
    Profitability
    Profit Margin0.00%Operating Margin-2792.00%
    ROE-47.10%ROIC-29.05%
    Financial Health
    Debt/Equity0.13xInterest Coverage-3822.40x
    Current Ratio17.76xQuick Ratio17.76x
    Trading Statistics
    Beta1.17Avg Volume4.72M
    52-Week High$7.3052-Week Low$3.46

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.18
    SMA 20$4.55
    SMA 50$5.31
    SMA 200$5.39
    EMA 10$4.11
    EMA 20$4.46
    EMA 50$5.03
    EMA 200$5.17

    MACD

    Line: -0.42Signal: -0.34Hist: -0.08

    ADX

    ADX: 32.9+DI: 10.6-DI: 36.0

    Aroon & PSAR

    Aroon Up20.0
    Aroon Down96.0
    PSAR$4.39

    Bollinger Bands

    Upper Band$5.52
    Lower Band$3.58
    %B Position4274%(Upper)
    Band Width0.08

    RSI (14-Day)

    Oversold
    27.2

    Momentum Oscillators

    Stoch %K7.5
    Stoch %D6.3
    Williams %R-82.8
    ROC (10d)-21.3%
    Momentum-1.01
    CCI (20d)-161.0
    MFI (14d)41.7

    Volatility Measures

    ATR (14d)$0.29(7.7%)
    StdDev (20d)0.49
    Hist Vol70.2%(High)

    Volume Flow

    VWAP$3.67
    OBV169.0M
    AD Line99.6M
    CMF (20d)-0.183

    Volume Metrics

    Avg Vol (20d)4.8M
    Vol Ratio0.9x
    VWMA (20d)$4.55

    Pivot Points

    R3$3.92
    R2$3.82
    R1$3.67
    Pivot Point$3.56
    S1$3.40
    S2$3.30
    S3$3.15

    Advanced Oscillators

    TSI-45.35
    Ultimate Osc36.9
    KST-216.09

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$5.49M$0$1.99M$2.30M$2.02M$1.79M$1.11M$3.41M$3.60M$4.75M
    Cost of Revenue$0$0$299,000$0$0$0$-625,000$0$0$0$366,000$0
    Gross Profit$0$0$5.49M$0$1.99M$2.30M$2.02M$1.79M$1.11M$3.41M$3.60M$4.75M
    Operating Expenses$47.35M$43.49M$33.78M$34.02M$28.74M$23.72M$21.95M$27.69M$22.41M$27.74M$19.85M$21.00M
    R&D$38.64M$33.81M$24.95M$25.75M$20.14M$15.56M$15.32M$14.95M$15.07M$20.66M$12.68M$11.79M
    SG&A$12.15M$9.68M$8.83M$8.28M$8.60M$8.16M$6.63M$7.90M$7.34M$7.08M$6.72M$8.59M
    Operating Income$-47,349,000$-43,486,000$-28,300,000$-34,024,000$-26,753,000$-21,421,000$-19,932,000$-25,898,000$-21,299,000$-24,330,000$-16,246,000$-16,250,000
    Interest Income$2.33M$2.59M$2.87M$3.17M$1.86M$1.33M$1.70M$2.11M$1.44M$1.69M$1.92M$1.11M
    Interest Expense$6,000$9,000$12,000$15,000$17,000$19,000$22,000$24,000$27,000$29,000$2.11M$1.47M
    Income Before Tax$-46,639,000$-42,410,000$-27,851,000$-32,733,000$-26,882,000$-21,529,000$-18,785,000$-25,524,000$-20,928,000$-24,061,000$47.74M$-117,087,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-46,639,000$-42,410,000$-27,851,000$-32,733,000$-26,882,000$-21,529,000$-18,785,000$-25,524,000$-20,928,000$-24,061,000$47.74M$-117,087,000
    EBITDA$-48,667,000$-44,692,000$-30,410,000$-35,601,000$-28,447,000$-22,553,000$-20,159,000$-27,313,000$-22,019,000$-25,400,000$48.30M$-116,394,000
    EBIT$-48,958,000$-44,987,000$-30,709,000$-35,887,000$-28,724,000$-22,836,000$-20,463,000$-27,607,000$-22,341,000$-25,725,000$47.93M$-116,725,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TSHA

    News

    Taysha Gene Therapies stock hits 52-week low at 3.69 USD

    Taysha Gene Therapies Inc. (TSHA) stock has fallen to a 52-week low of $3.69, representing a 27.55% decrease over the past year and a 51% drop from its 52-week high. This downturn follows a wider-than-expected loss in Q2...

    Investing.com•10/13/26•Bearish

    Four new hires get Taysha stock awards tied to 384,000 shares, plus rights to buy more.

    Taysha Gene Therapies granted equity awards to four new employees on October 1, 2026, as an inducement for employment...

    Stock Titan•10/2/26•Somewhat-Bearish

    Wolfe Research Initiates Taysha Gene Therapies(TSHA.US) With Buy Rating

    Wolfe Research has initiated coverage on Taysha Gene Therapies (TSHA.US) with a Buy rating. This indicates a positive outlook from the research firm regarding the company's stock performance.

    Moomoo•9/17/26•Bullish

    Taysha Gene Therapies, Inc. launches webinar to advance patient-centered Rett syndrome trials

    Taysha Gene Therapies, Inc. is promoting a webinar focused on advancing patient-centered clinical trials for Rett syndrome. The webinar, hosted by the Child Neurology Society and featuring Dr. Arthur Partikian...

    Traders Union•8/27/26•Bullish

    New Taysha Gene Therapies hires receive 349,000-share stock grant

    Taysha Gene Therapies (Nasdaq: TSHA) announced it granted 349,000 restricted stock units (RSUs) to three new employees on February 2, 2026...

    Stock Titan•8/24/26•Somewhat-Bullish

    TSHA Valuation and Fair Value

    P/E
    -9.3x
    P/FCF
    -10.4x
    P/B
    3.6x
    See GNG's fair value

    TSHA Profitability: Margins, ROIC and FCF

    Operating margin
    -2792.0%
    Net margin
    0.0%
    ROIC
    -29.1%
    ROE
    -47.1%
    FCF margin
    -2417.0%
    FCF yield
    -9.6%

    TSHA Competitors

    CompanyTicker
    Iradimed CoIRMD
    Vor Biopharma IncVOR
    Goodrx Holdings IncGDRX
    Omada Health, Inc. Common StockOMDA
    Cronos Group IncCRON
    Tandem Diabetes Care IncTNDM
    CareCloud, Inc.CCLDO
    Amphastar PAMPH

    Sector: Healthcare

    TSHA Analyst Ratings

    Consensus
    Buy
    Analysts
    12
    Strong Buy
    3
    Buy
    9
    Hold
    0
    Sell
    0
    Strong Sell
    0

    TSHA Bull Case vs Bear Case

    Bull case

    • TSHA grew quarterly revenue 171.3% year over year.
    • 100.0% of TSHA's analyst ratings are Buy or Strong Buy.

    Bear case

    • TSHA beat EPS estimates in 37.5% of its last 8 reported quarters.

    TSHA Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    2.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.13
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 3 down

    Frequently Asked Questions About TSHA

    Does TSHA pay dividends?

    Taysha Gene Therapies Inc (TSHA) does not currently pay a regular dividend.

    What is TSHA's market cap?

    Taysha Gene Therapies Inc (TSHA) has a market capitalization of $1.14B with a current stock price of $3.73.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In